PEN Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.1% compared to Penumbra's net margin of 12.41%. Penumbra's return on equity of 3.62% beat Boston Scientific's return on equity of 8.96%.

Penumbra has a consensus price target of $309.00, signalling upside risk potential of 10.84%. On the other hand Boston Scientific has an analysts' consensus of $115.75 which suggests that it could grow by 17.02%. Given that Boston Scientific has higher upside potential than Penumbra, analysts believe Boston Scientific is more attractive than Penumbra.

Penumbra has a beta of 0.559, which suggesting that the stock is 44.135% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Penumbra's net income of $39.2M is lower than Boston Scientific's net income of $566M. Notably, Penumbra's price-to-earnings ratio is 262.99x while Boston Scientific's PE ratio is 79.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.88x versus 8.78x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of 12.1% compared to Penumbra's net margin of -3.78%. Penumbra's return on equity of 3.62% beat ICU Medical's return on equity of -5.75%.

Penumbra has a consensus price target of $309.00, signalling upside risk potential of 10.84%. On the other hand ICU Medical has an analysts' consensus of $186.40 which suggests that it could grow by 40.96%. Given that ICU Medical has higher upside potential than Penumbra, analysts believe ICU Medical is more attractive than Penumbra.

Penumbra has a beta of 0.559, which suggesting that the stock is 44.135% less volatile than S&P 500. In comparison ICU Medical has a beta of 0.863, suggesting its less volatile than the S&P 500 by 13.724%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than ICU Medical quarterly revenues of $629.8M. Penumbra's net income of $39.2M is higher than ICU Medical's net income of -$23.8M. Notably, Penumbra's price-to-earnings ratio is 262.99x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.88x versus 1.35x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 12.1% compared to Penumbra's net margin of 7.87%. Penumbra's return on equity of 3.62% beat Merit Medical Systems's return on equity of 9.36%.

Penumbra has a consensus price target of $309.00, signalling upside risk potential of 10.84%. On the other hand Merit Medical Systems has an analysts' consensus of $117.45 which suggests that it could grow by 25.34%. Given that Merit Medical Systems has higher upside potential than Penumbra, analysts believe Merit Medical Systems is more attractive than Penumbra.

Penumbra has a beta of 0.559, which suggesting that the stock is 44.135% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.356%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Merit Medical Systems quarterly revenues of $355.2M. Penumbra's net income of $39.2M is higher than Merit Medical Systems's net income of $27.9M. Notably, Penumbra's price-to-earnings ratio is 262.99x while Merit Medical Systems's PE ratio is 46.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.88x versus 4.10x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of 12.1% compared to Penumbra's net margin of 41.51%. Penumbra's return on equity of 3.62% beat Semler Scientific's return on equity of 37.58%.

Penumbra has a consensus price target of $309.00, signalling upside risk potential of 10.84%. On the other hand Semler Scientific has an analysts' consensus of $71.00 which suggests that it could grow by 107.12%. Given that Semler Scientific has higher upside potential than Penumbra, analysts believe Semler Scientific is more attractive than Penumbra.

Penumbra has a beta of 0.559, which suggesting that the stock is 44.135% less volatile than S&P 500. In comparison Semler Scientific has a beta of 1.290, suggesting its more volatile than the S&P 500 by 29.027%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are larger than Semler Scientific quarterly revenues of $12.4M. Penumbra's net income of $39.2M is higher than Semler Scientific's net income of $29.2M. Notably, Penumbra's price-to-earnings ratio is 262.99x while Semler Scientific's PE ratio is 6.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.88x versus 4.86x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.